Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer's Currency, Patent Pressures Boost Allergan Merger's Importance

This article was originally published in Scrip

Executive Summary

Pfizer Inc.'s pending $160bn merger with Allergan PLC may be its best shot at significant revenue growth this year, since the company's 2015 revenue and earnings fell below 2014 totals due to foreign currency impacts and the loss of patent exclusivity for multiple products – factors that again could lead to flat growth during the current year, despite meaningful sales gains for certain products.

Advertisement

Related Content

Full Monty On Pfizer’s Failed 5-HT6 Alzheimer’s Drug Leaves Hope For Class

Topics

Advertisement
UsernamePublicRestriction

Register

SC064381

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel